BCAB
BioAtla (BCAB)
$69
About BioAtla (BCAB)
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Details
Daily high
$1.08
Daily low
$0.67
Price at open
$1.08
52 Week High
$4.02
52 Week Low
$0.67
Market cap
33.5M
Dividend yield
0.00%
Volume
6.2M
Avg. volume
863,829
P/E ratio
-.41
BioAtla News
Details
Daily high
$1.08
Daily low
$0.67
Price at open
$1.08
52 Week High
$4.02
52 Week Low
$0.67
Market cap
33.5M
Dividend yield
0.00%
Volume
6.2M
Avg. volume
863,829
P/E ratio
-.41